"As Gentris enters its second decade, the Company is fortunate to have experienced executives like Dr. David Drutz and Tim Gupton serving on the Board of Directors," said Rick Williams, CEO of Gentris Corporation. "Dr. Drutz and Mr. Gupton have been involved in many facets of the biopharma industry. They understand how to guide a senior management team and its advisors to create scientific innovation and generate high-growth commercial results."
"Pharmacogenomics is directed to understanding how drugs interact with our genetic makeup," said Dr. David Drutz, chair of the Gentris board of directors. "As such, pharmacogenomics enables therapeutic agents to be directed toward those individuals most likely to have a favorable clinical response and away from those most likely to suffer adverse effects. Pharmacogenomics serves as a centerpiece for the future of drug development in the pharmaceutical and biotechnology industries. I am delighted to be associated in such an important way with a well-established company that is working at the cutting edge in this exciting endeavor.""As an investor from Research Triangle Ventures," Tim Gupton said, "I've been associated with Gentris since its inception. Gentris has always been driven by excellent science and quality standards and has been a leader in helping the pharmaceutical industry to use genetic data to differentiate their drug candidates. With clinical biomarkers becoming an expectation for drug development, I'm confident that Gentris will remain a leader in the rapidly growing field of personalized medicine." About Gentris Corporation: Founded in 2001, Gentris is located in Research Triangle Park, NC, where it provides support for all phases of clinical studies and genomic biomarker programs. The Company works with academic and industry leaders to translate innovations in pharmacogenomics into safer, more effective medicines, which can lead to accelerated drug development and improvement in patient care globally. In the past year, Gentris significantly expanded its facility and onsite biorepository to meet the increased needs of biopharma clients, while maintaining a preeminent quality system. The Gentris team has collaborated with sponsors to incorporate pharmacogenomics into more than five hundred clinical trials around the world. Its scientists routinely design complex de novo genomic assays. The Company's Integrated BioRepository Solutions business unit manages study-site logistics, conduct genomic assessments, and store patient biospecimens. For additional information, please visit www.gentris.com or call 919.653.5534. Keywords: Gentris Corporation, Genomics, Clinical Genomics, Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Personalized Medicine, Individualized Medicine, Biomarkers, Genomic Assays, Genomic Methods, Hepatitis, Oncology, Cancer, Immunology, Biobanking, Biorepository, Biospecimens, Integrated BioRepository Solutions.